JP2017508806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508806A5 JP2017508806A5 JP2016575629A JP2016575629A JP2017508806A5 JP 2017508806 A5 JP2017508806 A5 JP 2017508806A5 JP 2016575629 A JP2016575629 A JP 2016575629A JP 2016575629 A JP2016575629 A JP 2016575629A JP 2017508806 A5 JP2017508806 A5 JP 2017508806A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- fxa
- fii
- deficiency
- hemophilia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 21
- 208000031220 Hemophilia Diseases 0.000 claims 6
- 208000009292 Hemophilia A Diseases 0.000 claims 6
- 230000007812 deficiency Effects 0.000 claims 5
- 108010074860 Factor Xa Proteins 0.000 claims 3
- 208000031169 hemorrhagic disease Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 108010094028 Prothrombin Proteins 0.000 claims 2
- 102100027378 Prothrombin Human genes 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 208000027276 Von Willebrand disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940039716 prothrombin Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- 208000002004 Afibrinogenemia Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 208000033131 Congenital factor II deficiency Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 206010016076 Factor II deficiency Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 claims 1
- 208000007646 Hypoprothrombinemias Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000036064 Surgical Blood Loss Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 230000009852 coagulant defect Effects 0.000 claims 1
- 201000007182 congenital afibrinogenemia Diseases 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940039715 human prothrombin Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000014508 negative regulation of coagulation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 201000007183 prothrombin deficiency Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953496P | 2014-03-14 | 2014-03-14 | |
| US61/953,496 | 2014-03-14 | ||
| PCT/US2015/020361 WO2015138847A1 (en) | 2014-03-14 | 2015-03-13 | Compositions of human prothrombin and activated factor x for improving hemostasis in the treatment of bleeding disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017508806A JP2017508806A (ja) | 2017-03-30 |
| JP2017508806A5 true JP2017508806A5 (OSRAM) | 2018-04-26 |
| JP6535036B2 JP6535036B2 (ja) | 2019-06-26 |
Family
ID=52727470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016575629A Active JP6535036B2 (ja) | 2014-03-14 | 2015-03-13 | 出血性疾患の治療における止血を改善するためのヒトプロトロンビン及び活性化第ｘ因子の組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150258182A1 (OSRAM) |
| EP (1) | EP3116534B1 (OSRAM) |
| JP (1) | JP6535036B2 (OSRAM) |
| CN (1) | CN106413744B (OSRAM) |
| AU (1) | AU2015229222C1 (OSRAM) |
| ES (1) | ES2742898T3 (OSRAM) |
| NZ (1) | NZ724105A (OSRAM) |
| TW (1) | TWI653047B (OSRAM) |
| WO (1) | WO2015138847A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI653047B (zh) | 2014-03-14 | 2019-03-11 | 百特製藥公司 | 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物 |
| US11744880B2 (en) | 2017-02-09 | 2023-09-05 | Csl Behring Gmbh | Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings |
| EP3590528A1 (en) * | 2018-07-06 | 2020-01-08 | Octapharma AG | Fx activation process and its use in the preparation of a fxa composition |
| CN118401262A (zh) | 2021-12-30 | 2024-07-26 | 巴克斯特国际公司 | 用于纤维蛋白密封剂的纤维蛋白原和凝血酶溶液以及纤维蛋白密封剂试剂盒 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4287180A (en) | 1980-01-28 | 1981-09-01 | Baxter Travenol Laboratories, Inc. | Method for treating blood clotting factor inhibitors |
| EP0796623B1 (de) * | 1996-03-20 | 2005-05-25 | Baxter Aktiengesellschaft | Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen |
| US9956272B2 (en) | 2007-05-30 | 2018-05-01 | Bio Products Laboratory Limited | Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same |
| EP2547371A1 (en) * | 2010-03-15 | 2013-01-23 | Ferrosan Medical Devices A/S | A method for promotion of hemostasis and/or wound healing |
| TWI653047B (zh) | 2014-03-14 | 2019-03-11 | 百特製藥公司 | 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物 |
-
2015
- 2015-03-12 TW TW104107965A patent/TWI653047B/zh active
- 2015-03-13 NZ NZ724105A patent/NZ724105A/en unknown
- 2015-03-13 ES ES15712018T patent/ES2742898T3/es active Active
- 2015-03-13 WO PCT/US2015/020361 patent/WO2015138847A1/en not_active Ceased
- 2015-03-13 JP JP2016575629A patent/JP6535036B2/ja active Active
- 2015-03-13 US US14/658,006 patent/US20150258182A1/en not_active Abandoned
- 2015-03-13 EP EP15712018.9A patent/EP3116534B1/en not_active Revoked
- 2015-03-13 CN CN201580022141.6A patent/CN106413744B/zh active Active
- 2015-03-13 AU AU2015229222A patent/AU2015229222C1/en active Active
-
2018
- 2018-12-21 US US16/231,195 patent/US11160850B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2704657T3 (es) | Focalización selectiva de la interacción CD40L/MAC-1 por inhibidores de péptidos pequeños y su uso para el tratamiento de inflamación y aterogénesis | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| JP2012095641A5 (OSRAM) | ||
| JP2012105650A5 (OSRAM) | ||
| JP2017508806A5 (OSRAM) | ||
| JP2014513952A5 (OSRAM) | ||
| JP2015512927A5 (OSRAM) | ||
| AR073567A1 (es) | Formulaciones de peptidos y sus usos. metodo | |
| HRP20170328T1 (hr) | Cjepivo pcsk9 | |
| JP2012513193A5 (OSRAM) | ||
| Burster et al. | Hindrance of the proteolytic activity of neutrophil-derived serine proteases by serine protease inhibitors as a management of cardiovascular diseases and chronic inflammation | |
| JP2017533910A5 (OSRAM) | ||
| JP2015514115A5 (OSRAM) | ||
| US11160850B2 (en) | Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders | |
| JP2017502036A (ja) | 血友病の予防的処置のための第ｉｘ因子を含む融合タンパク質およびその方法 | |
| JP2013538863A5 (OSRAM) | ||
| JP2014519514A (ja) | ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法 | |
| Negrier | Inhibitors to factor VIII: treatment of acute bleeds | |
| JP2013517782A5 (OSRAM) | ||
| ES2263582T3 (es) | Utilizacion del factor de crecimiento para prevenir o tratar cardiopatias isquemicas o accidentes cardiovasculares. | |
| ES2913934T3 (es) | Un producto de sustitución del factor de coagulación de la sangre para su uso en el tratamiento o la profilaxis de las hemorragias | |
| JP2016536368A5 (OSRAM) | ||
| Johnson et al. | Plasminogen activator inhibitor type-2 (PAI-2)/SerpinB2: a unique multifunctional serpin | |
| WO2022224249A1 (en) | Procoagulant peptides and use thereof | |
| RU2015115327A (ru) | Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера |